Compare Abercrombie & Fitch Co. (ANF) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Centene Corp — how do they compare? Abercrombie & Fitch Co. trades at $92.59 (market cap $4.14B), while Centene Corp trades at $68.39 (market cap $33.26B). The key difference: Centene Corp is far larger — about 8× Abercrombie & Fitch Co.'s market cap, and Centene Corp is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | CNC | |
|---|---|---|
Market Cap | $4.14B | $33.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $68.34 |
52-Week Low | $65.61 | $25.21 |
Enterprise Value | $4.81B | $25.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
Centene (CNC) trades at $67.35, down 0.37% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.06 and P/S of 0.17, but faces profitability challenges with a negative net income margin of -3.25% for 2025. Recent positive developments include the renewal of a key Illinois Medicaid contract and consistent earnings beats in recent quarters, supporting a strong analyst consensus with 61% buy ratings.
The outlook for CNC hinges on successful margin recovery initiatives and cost management. Investment opportunities lie in its undervalued metrics and stable revenue base, but risks include persistent negative profitability, regulatory pressures in healthcare, and execution challenges in improving medical cost controls. The consensus price target of $63.36 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
